PharmacovigilanceOfficial

FDA's acting commissioner sets out rare disease push and tailored review framework

🇺🇸 FDA CBER · Thu 05 Nov 2026

Kyle Diamantas says the agency approved 28 novel rare disease drugs and biologics in the past year, while nearly 95 percent of patients still lack an approved treatment.

Acting FDA Commissioner Kyle Diamantas has published a statement on rare diseases, describing them as the agency's most formidable challenge and its greatest opportunity to speed treatments and cures to patients. The item appears on the FDA CBER site and is dated 5 November 2026.

Mr Diamantas said the FDA has approved 28 novel drugs and biologics for rare diseases over the past year. He cited a first-in-class treatment for muscle loss in adults and children aged two and above with spinal muscular atrophy. He noted, however, that nearly 95 percent of rare disease patients still have no approved option. He also referred to Baby KJ, who received the first personalised CRISPR gene-editing therapy.

The statement says the agency launched the Rare Disease Framework Initiative last month with a public meeting that included feedback from 75 members of the rare disease community. The input will be used to shape and strengthen the initiative, which is meant to change how the FDA approaches product development and regulatory review for drugs and biologics. Mr Diamantas also said he convened a roundtable of rare disease advocates in one of his first actions as acting commissioner.

The planned framework would be tailored to the specific disease, patient needs, product type and available scientific evidence, while keeping the highest safety and effectiveness standards, according to the text. The FDA says it intends to bring patient experience into review earlier and more consistently. It is encouraging review teams to consult external experts on disease natural history, and it is promoting new technologies to streamline clinical development.

The piece sets out no specific rule change, requirement or timeline, so it signals policy direction rather than an immediate obligation.

What it means for your team

  • No new compliance obligation is announced; the item signals direction for rare disease development and review at the FDA.
  • Sponsors of rare disease drugs and biologics may wish to follow the Rare Disease Framework Initiative, as input from the public meeting will feed into its design.
  • Early patient-experience input and engagement with disease-specific external experts are stressed, which may be relevant to development planning and evidence strategy.
  • The FDA says it will keep its safety and effectiveness standards, even as the framework is tailored by disease and evidence.

Official source: FDA CBER ↗

Article written by VigiEye from the official source (FDA CBER). AI-assisted; check the source before acting.

More Pharmacovigilance All →